Safety profile of asparaginase Erwinia chrysanthemi in a large compassionate-use trial

Pediatric Blood and Cancer

Volumn 61, Issue 7, 2014, Pages 1232-1238

  Plourde, Paul V ^a   Jeha, Sima ^b   Hijiya, Nobuko ^c   Keller, Frank G ^d   Silverman, Lewis B ^e   Rheingold, Susan R ^f   Dreyer, Zoann E ^g   Dahl, Gary V ^h   Mercedes, Taheri ^a   Lai, Chinglin ^a   Corn, Tim ⁱ  

^a JAZZ PHARMACEUTICALS   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d EMORY UNIVERSITY   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^g TEXAS CHILDREN S HOSPITAL   (United States)

^h STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ Department of Clinical Oncology EUSA Pharma (an international division of Jazz Pharmaceuticals plc)   (United Kingdom)

Author keywords

Acute lymphoblastic leukemia; ALL; Asparaginase Erwinia chrysanthemi; Escherichia coli derived asparaginase; Hypersensitivity; Lymphoblastic lymphoma; Safety

Indexed keywords

AMINOTRANSFERASE; ASPARAGINASE; ASPARAGINASE MACROGOL; BACTERIAL ENZYME; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ANAPHYLAXIS; ANTICIPATORY NAUSEA AND VOMITING; ARTICLE; BLEEDING; BRAIN DISEASE; CANCER CHEMOTHERAPY; CHILD; COMPASSIONATE USE; CONTROLLED STUDY; DEHYDRATION; DIARRHEA; DRUG APPROVAL; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERAMMONEMIA; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; KETOACIDOSIS; LEUKOPENIA; LYMPHOBLASTOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; PANCREATITIS; PRIORITY JOURNAL; SEPSIS; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; VOMITING;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALL; ASPARAGINASE ERWINIA CHRYSANTHEMI; ESCHERICHIA COLI-DERIVED ASPARAGINASE; HYPERSENSITIVITY; LYMPHOBLASTIC LYMPHOMA; SAFETY;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; ASPARAGINASE; BACTERIAL PROTEINS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG HYPERSENSITIVITY; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PECTOBACTERIUM CHRYSANTHEMI; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECOMBINANT PROTEINS;

EID: 84899701304     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24938     Document Type: Article

References (38)

1. Howlader N, Noone AM, Krapcho M, et al., editors. SEER cancer statistics review, 1975-2010. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975_2010/. Based on November 2012 SEER data submission posted to the SEER website April 29, 2013. Accessed May 8, 2013.
2. Alvarnas JC, Brown PA, Aoun P, et al. For the National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology: Acute lymphoblastic leukemia, version 1.2013. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed May 8, 2013.
3. Silverman LB, Gelber RD, Dalton VK, et al. Improved outcome for children with acute lymphoblastic leukemia: Results of Dana-Farber Consortium Protocol 91-01. Blood 2001; 97:1211-1218.
4. Pession A, Valsecchi MG, Masera G, et al. Long-term results of a randomized trial on extended use of high dose l-asparaginase for standard risk childhood acute lymphoblastic leukemia. J Clin Oncol 2005; 23:7161-7167.
5. Pieters R, Hunger S, Boos J, et al. l-Asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase. Cancer 2011; 117:238-249.
6. Panetta JC, Gajjar A, Hijiya N, et al. Comparison of native E. coli and PEG asparaginase pharmacokinetics and pharmacodynamics in pediatric acute lymphoblastic leukemia. Clin Pharmacol Ther 2009; 86:651-658.
7. United States Food and Drug Administration. Drugs to be discontinued website. http://www.fda.gov/drugs/drugsafety/drugshortages/ucm050794.htm. Accessed May 8, 2013.
8. Asselin BL, Ryan D, Frantz CN, et al. In vitro and in vivo killing of acute lymphoblastic leukemia cells by l-asparaginase. Cancer Res 1989; 49:4363-4368.
9. Graham ML. Pegaspargase: A review of clinical studies. Adv Drug Deliv Rev 2003; 55:1293-1302.
10. Asselin BL, Whitin JC, Coppola DJ, et al. Comparative pharmacokinetic studies of three asparaginase preparations. J Clin Oncol 1993; 11:1780-1786.
11. Kamisaki Y, Wada H, Yagura T, et al. Reduction in immunogenicity and clearance rate of Escherichia coli l-asparaginase by modification with monomethoxypolyethylene glycol. J Pharmacol Exp Ther 1981; 216:410-414.
12. Ho DH, Brown NS, Yen A, et al. Clinical pharmacology of polyethylene glycol-l-asparaginase. Drug Metab Dispos 1986; 14:349-352.
13. Wang B, Relling MV, Storm MC, et al. Evaluation of immunologic crossreaction of antiasparaginase antibodies in acute lymphoblastic leukemia (ALL) and lymphoma patients. Leukemia 2003; 17:1583-1588.
14. Zalewska-Szewczyk B, Gach A, Wyka K, et al. The cross-reactivity of anti-asparaginase antibodies against different l-asparaginase preparations. Clin Exp Med 2009; 9:113-116.
15. Woo MH, Hak LJ, Storm MC, et al. Hypersensitivity or development of antibodies to asparaginase does not impact treatment outcome of childhood acute lymphoblastic leukemia. J Clin Oncol 2000; 18:1525-1532.
16. Raetz EA, Salzer WL. Tolerability and efficacy of l-asparaginase therapy in pediatric patients with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2010; 32:554-563.
17. Salzer WL, Devidas M, Shuster JJ, et al. Intensified PEG-l-asparaginase and antimetabolite-based therapy for treatment of higher risk precursor-B acute lymphoblastic leukemia: A report from the Children's Oncology Group. J Pediatr Hematol Oncol 2007; 29:369-375.
18. Panosyan EH, Seibel NL, Martin-Aragon S, et al. Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia: Children's Cancer Group Study CCG-1961. J Pediatr Hematol Oncol 2004; 26:217-226.
19. Vrooman LM, Stevenson KE, Supko JG, et al. Postinduction dexamethasone and individualized dosing of Escherichia coli l-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: Results from a randomized study-Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. J Clin Oncol 2013; 31:1202-1210.
20. Rizzari C, Conter V, Starý J, et al. Optimizing asparaginase therapy for acute lymphoblastic leukemia. Curr Opin Oncol 2013; 25:S1-S9.
21. Duval M, Suciu S, Ferster A, et al. Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: Results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood 2002; 99:2734-2739.
22. Salzer W, Asselin B, Supko JG, et al. Erwinia asparaginase achieves therapeutic activity after pegaspargase allergy: A report from the Children's Oncology Group. Blood 2013; 122:507-514.
23. Erwinaze (asparaginase Erwinia chrysanthemi) [package insert]. Langhorne, PA, EUSA Pharma (USA), Inc., an international division of Jazz Pharmaceuticals plc; November 2011.
24. Moghrabi A, Levy DE, Asselin B, et al. Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. Blood 2007; 109:896-904.
25. Shelton CM, Chhim RF, Christensen ML. Recent new drug approvals. Part 1: Drugs with pediatric indications. J Pediatr Pharmacol Ther 2012; 17:329-339.
26. Billett AL, Carls A, Gelber RD, Sallan SE. Allergic reactions to Erwinia asparaginase in children with acute lymphoblastic leukemia who had previous allergic reactions to Escherichia coli asparaginase. Cancer 1992; 70:201-206.
27. Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007; 25:813-819.
28. Pidaparti M, Bostrom B. Comparison of allergic reactions to pegasparaginase given intravenously versus intramuscularly. Pediatr Blood Cancer 2012; 59:436-439.
29. Evans WE, Tsiatis A, Rivera G, et al. Anaphylactoid reactions to Escherichia coli and Erwinia asparaginase in children with leukemia and lymphoma. Cancer 1982; 49:1378-1383.
30. Kearney SL, Dahlberg SE, Levy DE, et al. Clinical course and outcome in children with acute lymphoblastic leukemia and asparaginase-associated pancreatitis. Pediatr Blood Cancer 2009; 53:162-167.
31. Vrooman LM, Supko JG, Neuberg DS, et al. Erwinia asparaginase after allergy to E. coli asparaginase in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54:199-205.
32. Avramis VI, Sencer S, Periclou AP, et al. A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: A Children's Cancer Group study. Blood 2002; 99:1986-1994.
33. Pui CH, Burghen GA, Bowman WP, Aur RJ. Risk factors for hyperglycemia in children with leukemia receiving l-asparaginase and prednisone. J Pediatr 1981; 99:46-50.
34. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354:166-178.
35. Faderl S, Kantarjian HM, Talpaz M, Estrov Z. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. Blood 1998; 91:3995-4019.
36. Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010; 2010:21-29.
37. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112:1646-1654.
38. de Bont JM, Holt BV, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs. adult protocols in the Netherlands. Leukemia 2004; 18:2032-2035.